Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Doubleblind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xia Inhibitor, After a Recent Acute Coronary Syndrome

Project: Research

Project Details

StatusActive
Effective start/end date10/12/23 → 10/1/26

Funding

  • Janssen Research and Development LLC: $49,009.00